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Abstract
Globalization is having an ever growing impact on the field of vaccine production and distribution
in the world and domestically. In this article we examine the impact of taking a strategic approach
to vaccination programmes by all the relevant actors: WHO, UNICEF, national immunization pro-
grammes, and vaccine manufacturers and distributors. The review of the relevant literature indi-
cates that there are commonalities to the worldwide vaccination programmes. A comparative
analysis of various vaccination strategies recommended by WHO and the immunization calendars
of certain European countriesis made as well as an analysis of the Serbian vaccination pro-
gramme. New and more expensive vaccines will continue to appear on the market in increasingly
short periods of time.
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Introduction
The management of vaccination strategies in a global market is
growing in importance as new challenges arise. The development of
new technologies, and business environment of the new age have
resulted in the need for the application of strategic management [1]
as a ‘tool’ which, in a swiftly changing environment, can help orga-
nizations achieve their objectives more efficiently and effectively by
understanding their internal and external environments.
Globalization has enabled the free flow of resources, goods and
workforce and may be perceived as one of the external environment
factors impacting on the solutions for worldwide vaccination and
the defined national strategies.
The World Health Organization—WHO [2] defines a vaccine as
‘a biological preparation that improves immunity to a particular dis-
ease. The agent stimulates the body’s immune system to recognize
the agent as foreign, destroys it, and “remembers” it, so that the
immune system can more easily recognize and destroy any of these
microorganisms that it later encounters’.
The vaccine manufacturing process itself is complex and varies
from vaccine to vaccine.
In this article, we will examine the current state of vaccination
and will project the future trends that may develop in the global and
domestic vaccine market. We hypothesize that the application of
strategic management approach increases the effectiveness and effi-
ciency of organizations for vaccine production and distribution.
Methods
The data has been obtained from sources such as literature review
of the strategic documents of WHO, UNICEF, national vaccination
calendars, reports by relevant European and national institutions,
literature in the field of immunization, and relying on the legislation
regulating this field.
Primarily, official resources at the national and international
level have been used. This article is based on review of the previous
research, statistic data, facts presented at the professional meetings,
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etc. Collected data have been summarized and studied. In order to
describe the subject of the research better, different immunization
models have been presented by means of comparative analysis.
The author’s aim was contribution to theory and practice to
which the article refers.
Results
Contemporary global trends dictate that vaccine manufacturers har-
monize their production with the high standards of Good
Manufacturing Practices (GMP). GMP is ‘the aspect of quality
assurance that ensures that medicinal products are consistently pro-
duced and controlled to the quality standards appropriate to their
intended use and as required by the product specification’ [3].
In the future, one can expect the further advancement of proce-
dures in vaccine manufacture and distribution, and the upgrading of
guidelines based on GMP and Good Distribution Practice (GDP)
standards. The key issues that were found are as follows.
Climate
There are specific challenges based on the climate zone of a particu-
lar country, i.e. regional distributors face various challenges in the
delivery of vaccines, in the form of high or low external tempera-
tures, the level of infrastructure development, access to locations
that are hard to reach and without the necessary infrastructure.
Changing environment
In the field of vaccine production, one requires standardization of
processes and procedures with the upgrading of guidelines based on
GMP and GDP.
The vaccine market is growing rapidly and there is increased
investment in accelerated technological development, resulting in
expensive vaccines. This is impacted on by the mergers of major
pharmaceutical companies and a change in the type of vaccine
needed for the young and the elderly.
Role of organizations
WHO’s and UNICEF’s play an important part in the increasing vac-
cination coverage of the world population. The WHO guidelines
provide the framework for national programmes and this determines
the success rate of the programme by providing the standards to be
attained.
To achieve this multinational companies deploy strategic man-
agement strategies to meet the needs of international programmes.
An evidence-based, cost-effective, safe and efficient immunization
system is an integral part of a well-functioning health system [4].
Local requirements
When planning the immunization schedule, each country should
take into consideration the local epidemiological, programming and
political situation, as well as the resources at its disposal [5]. Based
on the data from Table 1, there is a noticeable trend of the constant
introduction of new vaccines for the prevention of as many diseases
as possible.
Parallel to the entry of new vaccines, there is the gradual cessation
of administering vaccines against diseases which have been eradicated
or are under control. For example, vaccine against tuberculosis
(BCG) at birth, has been removed from the immunization calendar in
nine EU countries (Austria, Belgium, Denmark, Germany, Iceland, Italy,
the Netherlands, Slovakia, Spain), while a number of member states
administer it only to certain (at-risk) groups [6]. This is related to the
risk profile of the population in each country.
For the purpose of making a comparison between the vaccin-
ation coverage in the Republic of Serbia to that in other countries,
data of the WHO register has been accessed. The percentage of the
BCG vaccination in the Republic of Serbia amounted to 99%
(2011), 97.92 (2012) and 97% (2013) [7]. In view of the above-
mentioned administration of vaccination against tuberculosis in
immunization calendars in the countries referred to in Table 1, the
comparison was made with the countries in the region, including
Hungary, as one of the countries analysed.
The percentage of coverage in the countries of the region (Bosnia
and Herzegovina, Montenegro, Macedonia, Croatia, Hungary,
Bulgaria and Romania) ranged from 93 to 99% in the said period
[7]. It can be concluded from the foregoing that Serbia’s coverage
corresponds to average values recorded in the region, where the vac-
cine against tuberculosis has remained in the compulsory immuniza-
tion calendar.
An analysis of the lists of recommended vaccines for immuniza-
tion by EU countries indicates that the introduction of new, polyva-
lent vaccines can be expected in the future, while at the same time
certain specificities of national immunization policies will be main-
tained. The EU Council ‘recognizes that immunization programmes
require sustainable access to long-term funding and quality supply,
and considers it necessary that policies to encourage vaccine
research are supported within the Union, taking into account also
the financial constraints, in order to make safer and more effective
vaccines available’ [4].
One can identify potential trends of further optimal evolution in
Serbia pertaining to the introduction of the pneumococcal vaccine as
being compulsory for the entire population (in accordance with
WHO recommendations) and the introduction of the meningococcal
vaccine in line with other European Union countries.
Keeping in mind the growth in dispersion of the HPV vaccine in
Europe, together with application and the expansion dynamic in the
European Union countries, we can expect this vaccine to be added
to the Serbian immunization calendar in the coming years.
Discussion
Strategic approach to immunization
Given the importance the vaccination programmes, it is evident that
a strategic management approach is an appropriate response to the
challenges of global immunization, the World Health Organization
and UNICEF developed the Global Immunization and Vision
Strategy 2006–15 [8]. This joint document has 24 strategies divided
into four strategic areas.
Beside the WHO and UN agencies, other vaccine market actors
are also aware of the importance of a strategic approach to the vac-
cine process. According to some authors, the appropriate response is
‘a challenge for policy makers and immunization stakeholders’ [9].
Every country defines the immunization programme for its citi-
zens depending on various factors—geographic location, economic
parameters, population size, living conditions, cultural characteris-
tics, etc. The competent national institutions determine the so-called
‘immunization calendar’, which encompasses a list of vaccines, the
number of doses and the age at which each of the vaccines included
is administered.
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According to UNICEF and WHO data, in 2013 there were 145
countries with a 3–5-year strategic national immunization plan.
Among the 29 countries without multiyear national immunization
plans included France, the country of traditional vaccine manufac-
turer Pasteur, as well as Germany and most Scandinavian countries.
For vaccines to arrive from the manufacturer to the end users
safely and with undiminished quality, WHO has developed a group
of guidelines called GDP, which are a logical extension of GMP.
The Vaccine Storage and Handling Toolkit [10] lists as import-
ant elements of the system the vaccine storage and handling proto-
cols, a regular storage plan and a plan of action in the event of
returning a lot or an emergency situation, staff (adequate number,
expertise and training), equipment (measuring devices, temperature
monitors, etc.) and equipment technical maintenance, strict tempera-
ture control, stock management, and the vaccine receipt and ship-
ment procedures.
The application of strategic management is evident in the oper-
ational processes of global vaccine manufacturers and distributors
who are significant vaccine market actors. This is key in ensuring
that they can deliver on their ‘mission’ of ensuring the delivery of
safe and effective vaccines and in investing efforts in the develop-
ment and discovery of new vaccines. In this sense, the strategies
applied by these companies in their organization focus predomin-
antly on the ‘vision’ of creating a world devoid of diseases that can
be prevented by vaccination.
Globalization as a business factor
The term globalization refers to the growth of mutual dependence
between the markets of national states [1]. The globalization trend,
initiated in the late 20th century, continues in the 21st century. It is
a complex, multidimensional process present in all sectors of the
economy and society. In that sense, its influence is visible in the pro-
duction and distribution of vaccines as well.
The vaccine market has shown rapid growth in recent times;
hence its value increased from five billion dollars in 2000 to almost
24 billion dollars in 2013, and is expected to reach 100 billion by
2025. WHO data indicates that five large multinational companies
manufacture around 80% of global vaccine quantities [11].
Communicable diseases have become a global problem requiring a
global response. As a result, there is a noticeable presence of global-
ization in the vaccine market and, this market will continue to
attract investment in new technologies and new vaccines. The WHO
states that, ‘the increasing globalization in the production and distri-
bution of these biological medicines has opened new possibilities to
better manage public health concerns, but has also raised questions
about the equivalence and interchangeability of medicines procured
across a variety of raw materials’ [12].
The Global Vaccine Action Plan (GVAP) constitutes the founda-
tion of a legal framework for equal access to vaccines worldwide.
The aim is to achieve the established goal of making vaccination
coverage in every part of the world over 80% by 2020 [13].
Immunologists constantly face new challenges in the form of
contributing to the eradication of known viruses, the development
of new vaccines and a strategic approach to preserving and
improving the population’s health. As a result of the noticeable
increase in the number of cases of meningitis caused by
Haemophilus influenzae among children in the 1970s and 1980s, a
vaccine against this bacteria was developed and added to the
immunization calendar by numerous countries [14]. In 1997, just
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immunization programmes, whereas by 2014 this number had
increased to 192 countries.
In Republic of Serbia in 2013, the Hib vaccination coverage
amounted to 92%, which is slightly lower compared to other ana-
lysed countries in Table 1, where the vaccination coverage ranged
from 94 to 99% with the exception of Iceland with 91% coverage
reported for that year. With regard to the region, the average
coverage is lower compared to the above-mentioned coverage in
the countries referred to in Table 1, ranging from 87% (Bosnia
and Herzegovina), 96% (Croatia) to 99% (Hungary) [7].
Nevertheless, according to the data in Table 3, the vaccination
coverage in Serbia in 2015 testifies to the growing coverage trends
in our country which correspond to the trends in the analysed
European countries.
To prevent pertussis, i.e. whooping cough, all EU countries
administer the acellular vaccine (acP). Poland has kept the whole
cell vaccine (wcP) and the acellular variant is used only as the fifth
dose [6]. It is interesting to note that vaccination against pertussis
in Serbia used to be administrated using the combined DTP vaccine
(Aldipete-Т® by the Torlak Institute of Virology, Vaccines and
Sera), which contains whole cell pertussis. The new Rulebook on
Immunization and Manner of Protection with Medicines in Serbia
came into force with effect from 1 January 2015, thereby launch-
ing the administration of the pentavalent vaccine within the com-
pulsory immunization calendar, which also contains acellular
pertussis.
Regardless of the vaccine form, all the countries referred to in
Table 1 consider the administration of this vaccine one of the main
vaccines in the compulsory vaccination programme.
In the analysis of the data from the WHO register for the period
2011–13 [7], it can be seen that Iceland had the lowest vaccination
coverage of 91% (2013), whereas the coverage in other analysed
countries in this 3-year period ranged between 95 and 99%. The
DTP3 vaccine coverage in Serbia in 2013 was 95%, which is slightly
lower than in other analysed countries having the following results:
Germany and Great Britain 96%; Italy 97%; France, the Czech
Republic and Hungary 99%.
The aforementioned vaccination coverage percentage in Serbia
amounting to 95% in 2015, according to the data shown in
Table 3, indicates a consistency in administration and the room for
further coverage growth.
Table 2 is based on the WHO recommendations on the list of
vaccines for children in certain regions, children in high-risk popula-
tions and children included in immunization programmes with cer-
tain characteristics. The recommendations mostly do not pertain to
Europe; hence, we find few applications with the immunization pro-
grammes observed. The purpose of this overview is to provide a
broader scope, which in globalization circumstances impacts the
trends in the field of vaccination at a national level (in the analysed
countries).
The herpes zoster vaccine is part of the programme in just three EU
member countries: Austria, France, UK and the Czech Republic where
it is registered but not yet available [6]. In this sense, one can expect
the further expansion of administration of this vaccine in Europe.
The vaccine against hepatitis A is present in just five EU coun-
tries: Austria, Belgium and Cyprus for certain groups, the Czech
Republic, and Greece for high-risk groups only [6]. Given that the
WHO recommends the administering of this vaccine only to the
high-risk population, the further trend of more and more countries
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Vaccination in Serbia
The beginnings of obligatory vaccination in Serbia date back to
1839. Following the European trends of that time, the first produc-
tion of vaccines in Serbia started in 1900 in Nis [16].
For many years, the Torlak Institute of Virology, Vaccines and
Sera has been manufacturing and distributing vaccines for compul-
sory immunization, prescribed by the Rulebook on Immunization
and Manner of Protection with Medicines and the Calendar of
Compulsory Vaccination in the Republic of Serbia.
Table 3 presents the results of the immunization carried out in
the Republic of Serbia in 2015 [17]. It stems from the overview that
the percentage of immunization by vaccines from the compulsory
immunization programme was over 80%. The MMR vaccination at
the age of two and the revaccination at the age of seven show less
high coverage, with a scope of 84 and 87.5%. In the meantime, vac-
cines included in our compulsory immunization calendar in 2005—
the vaccine against hepatitis B and in 2006—Hib vaccine, record
first dose coverage of 91.5 and 95%.
The immunization calendar in Serbia has changed over the years.
If we look back on the vaccines from the compulsory immunization
defined by the Rulebook on Immunizations from 1991, on the list
we will find the vaccines BCG, DTP, OPV, DT, dT, TT, the mono-
vaccine against pertussis, and the vaccine against measles and
mumps, whereas vaccination against rubella was compulsory only
for female children [18]. In this sense, the immunization calendar in
Serbia has changed and expanded to suit the needs of the popula-
tion, in accordance with the new challenges of disease eradication
by vaccination.
Conclusion
Modern environment for the production and distribution of vaccines
is characterized by globalization. In a dynamic environment, use of
strategic management by all players in the vaccine market—WHO,
UNICEF, national institutions, manufacturers and distributors of vac-
cines—contributed to increasing immunization coverage worldwide.
Each country develops its own national immunization strategy,
relying on WHO guidelines but respecting national characteristics—
climate, local epidemiological, political and financial situation.
Further standardization and upgrading of GMP and GDP
guidelines is expected.
Gradual cessation of administering vaccines against diseases
which have been eradicated or are under control at the same time
will be followed by the introduction of new vaccines and broadening
of the immunization calendars. Therefore, in line with global
changes, one may expect the enrichment of the immunization calen-
dar in Serbia in terms of introducing the pneumococcal vaccine as
compulsory for the entire population, as well as adding the HPV
vaccine to the Serbian immunization calendar in the coming years.
In Europe, further expansion of administration of the herpes zos-
ter vaccines expected, while further trend for the vaccine against
hepatitis A is increasing the number of countries adding this vaccine
to their programmes for certain groups of population. Global pro-
cesses face the European Union with new challenges, that require
new range of knowledge and new business strategy [19].
The vaccine market is growing rapidly and the accelerated
technological development is being increasingly invested in, resulting
in expensive vaccines.
The hypothesis that the application of strategic management
approach increases both the effectiveness and the efficiency of orga-
nizations for vaccine production and distribution has been con-
firmed. The global goal of all parties is creating a world devoid of
diseases that can be prevented by vaccination.
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DTP/DTaP-IPV-Hib rev. 1 88.7
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At age 7
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Communicable diseases—results of conducted immunisation in Republic
of Serbia, 2015. Health Statistical Yearbook of Republic of Serbia 2015,
2016 June: p. 418.
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